MedPath

NEUROCENTRIA, INC.

NEUROCENTRIA, INC. logo
🇺🇸United States
Ownership
Private
Established
2005-01-01
Employees
1
Market Cap
-
Website
http://www.neurocentria.com

Clinical Trials

5

Active:0
Completed:3

Trial Phases

1 Phases

Phase 2:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
5 (100.0%)

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Phase 2
Recruiting
Conditions
ADHD
Interventions
Drug: NRCT-101SR, NRCT-202XR
First Posted Date
2024-11-04
Last Posted Date
2025-03-12
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
60
Registration Number
NCT06673368
Locations
🇺🇸

Accel Research Site-Maitland Clinical Research Unit, Maitland, Florida, United States

🇺🇸

iResearch Atlanta, Decatur, Georgia, United States

🇺🇸

CenExel iRS - iResearch Savannah, Savannah, Georgia, United States

and more 2 locations

Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD

Phase 2
Recruiting
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
First Posted Date
2024-01-22
Last Posted Date
2025-03-12
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
160
Registration Number
NCT06215144
Locations
🇺🇸

Advanced Research Center, Inc, Anaheim, California, United States

🇺🇸

Accel Research Sites - Lakeland Clinical Research Unit, Lakeland, Florida, United States

🇺🇸

Accel Research Sites Network - Maitland, Maitland, Florida, United States

and more 9 locations

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2
Completed
Conditions
ADHD
Interventions
Drug: Placebo
First Posted Date
2023-01-13
Last Posted Date
2025-06-03
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
223
Registration Number
NCT05683249
Locations
🇺🇸

Collaborative Neuroscience Network, Garden Grove, California, United States

🇺🇸

Accel Research Sites, Maitland, Florida, United States

🇺🇸

Miami Dade Medical Research Institute, Miami, Florida, United States

and more 5 locations

Comparison of MMFS Dosages in Older Adults

Phase 2
Completed
Conditions
Anxiety
Depression
Cognitive Impairment
Sleep Quality
First Posted Date
2018-07-26
Last Posted Date
2020-09-09
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
9
Registration Number
NCT03601169
Locations
🇺🇸

Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States

Efficacy and Safety of MMFS in Early AD

Phase 2
Completed
Conditions
Alzheimer Disease
First Posted Date
2018-05-22
Last Posted Date
2020-09-09
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
10
Registration Number
NCT03531684
Locations
🇺🇸

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.